Volume 146, Issue 4, Pages e1 (April 2014)

Slides:



Advertisements
Similar presentations
Lecture 3 clinical immunology Antigen Presenting Cells
Advertisements

Don C. Rockey  Clinical Gastroenterology and Hepatology 
Oxidants and antioxidants in alcohol-induced liver disease
CELL-MEDIATED IMMUNITY RAHUL KUMAR LOHANA 2K16/MB/50 INSTITUTE OF MICROBIOLOGY UNIVERSITY OF SINDH, JAMSHORO.
Volume 154, Issue 5, Pages (April 2018)
Cellular and Molecular Mechanisms of Liver Injury
Major Histocompatibility Complex
Drug-induced liver injury part II
Volume 154, Issue 5, Pages (April 2018)
Pathogenesis of Liver Injury in Acute Liver Failure
Inflammation and Colon Cancer
Oxidants and antioxidants in alcohol-induced liver disease
Immunology Cell Volume 100, Issue 1, Pages (January 2000)
Obesity Heats Up Adipose Tissue Lymphocytes
Don C. Rockey  Clinical Gastroenterology and Hepatology 
Cellular and Molecular Mechanisms of Liver Injury
Volume 142, Issue 6, Pages (May 2012)
K. Lenhard Rudolph, Daniel Hartmann, Oliver G. Opitz  Gastroenterology 
Microbial Influences in Inflammatory Bowel Diseases
Alcohol and toxicity Journal of Hepatology
Gallstone Disease and Cancer Risk: Finding the Bug in the System
Volume 61, Issue 6, Pages (June 2002)
Mechanisms of Drug-Induced Allergy
Is Hepatitis C Virus Carcinogenic?
Tumor necrosis factor: Biology and therapeutic inhibitors
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 
Roles for Chemokines in Liver Disease
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Benoit Chassaing, Arlette Darfeuille–Michaud  Gastroenterology 
Arun J. Sanyal, Veronica Miller  Gastroenterology 
Volume 134, Issue 5, Pages (May 2008)
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Volume 150, Issue 4, Pages (April 2016)
Volume 69, Issue 4, Pages (October 2018)
From immunosuppression to tolerance
Inflammation, Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer  Ilya Gukovsky, Ning Li, Jelena Todoric,
Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Pathogenesis of Liver Injury in Acute Liver Failure
Evolving models of the immunopathogenesis of T cell–mediated drug allergy: The role of host, pathogens, and drug response  Katie D. White, MD, PhD, Wen-Hung.
The lymphoid liver: Considerations on pathways to autoimmune injury
Autophagy and senescence in fibrosing cholangiopathies
Volume 146, Issue 5, Pages (May 2014)
Volume 140, Issue 2, Pages e4 (February 2011)
Roles for KRAS in Pancreatic Tumor Development and Progression
Autophagy, Microbial Sensing, Endoplasmic Reticulum Stress, and Epithelial Function in Inflammatory Bowel Disease  Arthur Kaser, Richard S. Blumberg 
Genetic Distinctions in Patients With Primary Sclerosing Cholangitis: Immunoglobulin G4 Elevations and HLA Risk  Evaggelia Liaskou, Gideon M. Hirschfield 
Microbes, Microbiota, and Colon Cancer
Volume 118, Issue 2, Pages (February 2000)
Gallstones: Bad Company for the Steatotic Liver
Volume 63, Issue 2, Pages (August 2015)
A systems view of genetics in chronic kidney disease
Herbert Tilg, Gökhan S. Hotamisligil  Gastroenterology 
Volume 154, Issue 6, Pages e1 (May 2018)
Albert J. Czaja, Michael P. Manns  Gastroenterology 
The Role of TIM-4 in Food Allergy
Diarmaid Dominic Houlihan, Philip Noel Newsome  Gastroenterology 
Volume 148, Issue 3, Pages (March 2015)
Probiotics, Enteric and Diarrheal Diseases, and Global Health
The Gastrointestinal Tumor Microenvironment
Volume 142, Issue 4, Pages e6 (April 2012)
Christoph Becker, Alastair J. Watson, Markus F. Neurath 
New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity  Munir Pirmohamed, PhD, FRCP, David A.
Inflammation 2010: New Adventures of an Old Flame
A Necrotic Liver Mass Gastroenterology
Orchestration of the immune response by dendritic cells
Lisa M. Wheatley, MD, MPH, Marshall Plaut, MD, Julie M
A Unique Subset of Peyer's Patches Express Lysozyme
Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases  Louis J. Cohen, Judy H. Cho,
Tumor necrosis factor: Biology and therapeutic inhibitors
Presentation transcript:

Volume 146, Issue 4, Pages 914-928.e1 (April 2014) Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives  Robert J. Fontana  Gastroenterology  Volume 146, Issue 4, Pages 914-928.e1 (April 2014) DOI: 10.1053/j.gastro.2013.12.032 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 Factors implicated in the pathogenesis of idiosyncratic DILI. (A) Drug factors have not been reliably associated with liver injury in preclinical test systems or in patients with DILI. However, drug-drug or drug-disease interactions could alter the concentration of a drug or reactive metabolite at a cellular level involved in the initiation, maintenance, or resolution of liver injury. (B) Clinical host risk factors such as age, body weight, and body mass index have only rarely been implicated in the pathogenesis of DILI. However, recent GWAS have shown consistent associations between various single nucleotide polymorphisms in the HLA region and susceptibility to idiosyncratic DILI. (C) The microenvironment and macroenvironment vary greatly among patients receiving medications. However, coffee, alcohol consumption, and diet have not been identified as bona fide risk factors for DILI. The recent development of powerful transcriptomic, metabolomic, and microbiome methods may improve our understanding of environmental factors in the pathogenesis of DILI using advanced bioinformatics and systems biology approaches. Gastroenterology 2014 146, 914-928.e1DOI: (10.1053/j.gastro.2013.12.032) Copyright © 2014 AGA Institute Terms and Conditions

Figure 2 Potential mechanism(s) involved in the pathogenesis of idiosyncratic DILI. It is plausible that several cellular mechanisms may be involved in the pathogenesis of DILI. One major hypothesis of the pathogenesis of idiosyncratic DILI is the inadvertent generation of a reactive metabolite or parent drug-protein complex that can directly or indirectly mediate damage to intracellular proteins and/or organelles, resulting in the initiation of “danger” signals. Patients with DILI may be uniquely susceptible to developing liver injury from reduced detoxification, adaptation, or tolerance pathways that would normally rescue damaged hepatocytes or an increased likelihood of “bioactivation” pathways. In the hapten hypothesis, the drug-protein or metabolite-protein adduct leads to inadvertent activation of the adaptive immune system. Alternatively, in nonimmune mechanisms, damage-associated molecular pathway proteins such as HMGB-1, heat shock proteins, or cellular DNA released from necrotic cells lead to the recruitment of localized tissue injury. Cytokines, chemokines, and costimulatory molecules may play an integral role in macrophage activation and magnification of the damage-associated molecular pattern response via their impact on drug-metabolizing enzyme activity, the density of HLA molecules on antigen-presenting cells, the ability of the presented antigens to activate T cells, and the ability of activated T cells to cause hepatocyte death. ER, endoplasmic reticulum; BSEP, bile salt export pump. Gastroenterology 2014 146, 914-928.e1DOI: (10.1053/j.gastro.2013.12.032) Copyright © 2014 AGA Institute Terms and Conditions

Figure 3 Proposed role of aberrant immunity in the pathogenesis of DILI. Drugs are small molecules capable of binding to serum proteins under normal physiological circumstances for transport, metabolism, and elimination. In most instances, a drug-protein conjugate will not elicit a host immune response. However, a minority of individuals with specific class II HLA alleles that are ubiquitously expressed may be uniquely predisposed to have the native drug-protein or drug-metabolite-protein conjugate activate an antigen presenting cell such as a dendritic cell or macrophage. The processing and handling of drug-protein conjugates in these subjects can then inadvertently activate T-cell receptors, which may proliferate and mediate end-organ damage. MHC, major histocompatibility complex. Gastroenterology 2014 146, 914-928.e1DOI: (10.1053/j.gastro.2013.12.032) Copyright © 2014 AGA Institute Terms and Conditions